Glaukos (FRA:6GJ) Cyclically Adjusted Revenue per Share: €6.47 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6GJ Glaukos Corp FRA:6GJ
80 GF Score
Price €143.00
GF Value €123.37
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Glaukos Cyclically Adjusted Revenue per Share?

Glaukos FRA:6GJ -1.38% 80 Cyclically Adjusted Revenue per Share is €6.47 as of Jun. 2026. GuruFocus rates FRA:6GJ with a GF Score™ of 80/100 and a GF Value™ of €123.37 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Glaukos's adjusted revenue per share for the three months ended in Jun. 2026 was €2.739. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €6.47 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Glaukos's average Cyclically Adjusted Revenue Growth Rate was 14.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-04), Glaukos's current stock price is €143.00. Glaukos's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €6.47. Glaukos's Cyclically Adjusted PS Ratio of today is 22.10.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Glaukos was 23.74. The lowest was 9.92. And the median was 16.17.


Glaukos  (FRA:6GJ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Glaukos's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=143.00/6.47
=22.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Glaukos was 23.74. The lowest was 9.92. And the median was 16.17.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Glaukos Cyclically Adjusted Revenue per Share Related Terms


Glaukos Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Glaukos's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos Cyclically Adjusted Revenue per Share Chart

Glaukos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 5.48 6.44 5.81

Glaukos Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.31 5.56 5.81 5.97 6.47

FRA:6GJ vs BRKR, BIO, GMED: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Glaukos's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Glaukos's Cyclically Adjusted PS Ratio falls into.


FRA:6GJ
80GF Score
Glaukos Corp FRA:6GJ
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glaukos Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Glaukos's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.739/333.9520*333.9520
=2.739

Current CPI (Jun. 2026) = 333.9520.

Glaukos Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.712 241.428 0.985
201612 0.849 241.432 1.174
201703 0.890 243.801 1.219
201706 1.071 244.955 1.460
201709 0.900 246.819 1.218
201712 1.018 246.524 1.379
201803 0.939 249.554 1.257
201806 1.057 251.989 1.401
201809 1.059 252.439 1.401
201812 1.319 251.233 1.753
201903 1.321 254.202 1.735
201906 1.422 256.143 1.854
201909 1.442 256.759 1.876
201912 1.076 256.974 1.398
202003 1.144 258.115 1.480
202006 0.632 257.797 0.819
202009 1.231 260.280 1.579
202012 1.335 260.474 1.712
202103 1.249 264.877 1.575
202106 1.400 271.696 1.721
202109 1.288 274.310 1.568
202112 1.381 278.802 1.654
202203 1.241 287.504 1.441
202206 1.452 296.311 1.636
202209 1.512 296.808 1.701
202212 1.408 296.797 1.584
202303 1.442 301.836 1.595
202306 1.537 305.109 1.682
202309 1.502 307.789 1.630
202312 1.545 306.746 1.682
202403 1.589 312.332 1.699
202406 1.753 314.175 1.863
202409 1.583 315.301 1.677
202412 1.812 315.605 1.917
202503 1.742 319.799 1.819
202506 1.881 322.561 1.947
202509 1.982 324.800 2.038
202512 2.125 324.054 2.190
202603 2.245 330.213 2.270
202606 2.739 333.952 2.739

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €6.47 mean?
Glaukos (FRA:6GJ) has a Cyclically Adjusted Revenue per Share of €6.47 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Glaukos and its competitors.
Is Glaukos' Cyclically Adjusted Revenue per Share too high?
Glaukos' current Cyclically Adjusted Revenue per Share is €6.47. Overall, Glaukos has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Cyclically Adjusted Revenue per Share compare to BRKR and BIO?
Glaukos' Cyclically Adjusted Revenue per Share of €6.47 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Glaukos and its competitors. Glaukos's current Cyclically Adjusted Revenue per Share is €6.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (FRA:6GJ) is currently considered Modestly Overvalued. The stock's GF Value™ is €123.37, compared to a current price of €143.00 — trading 15.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €6.47. Glaukos' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Glaukos (FRA:6GJ), the current Cyclically Adjusted Revenue per Share is €6.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (FRA:6GJ) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of €143.00 is trading 15.9% above its estimated GF Value™ of €123.37. GuruFocus considers Glaukos to be Modestly Overvalued.

Key valuation signals for FRA:6GJ:

  • Cyclically Adjusted Revenue per Share: €6.47
  • GF Value™: €123.37 vs. price of €143.00 (15.9% above fair value)
  • GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the FRA:6GJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Glaukos Business Description

Other Exchanges GKOS:USA
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
80GF Score

Get the complete analysis for FRA:6GJ

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€143.00
Price
€123.37
GF Value